A 2-month-old infant who weighs 11 lb is prescribed to receive acetaminophen 8 mg/kg by oral liquid. The drug on hand is acetaminophen liquid with a concentration of 80 mg/0.8 mL. How many milliliters is the correct dose for this patient?
What is the answer?
0.4
You might also like to view...
A PHN is developing a measurable outcome health status indicator that can be used at the indi-vidual level of practice. Which of the following would the nurse most likely use?
a. A 50-year-old woman receives annual mammograms b. School absences in a community decline c. Teachers have increased awareness of health problems d. Those in poverty utilize the free mammo-gram program
Which of the following major problems results from the denial of preventive services (such as prenatal care, dental care, and immunizations) to any given population?
a. spiraling costs for emergency medical services b. health maintenance organizations losing money c. extensive waiting lists for clinic health care services d. closing of small community hospitals
Parents of a child with growth hormone deficiency ask the nurse about the cost of growth hormone, saying that they have heard it is expensive and they have little income. Which of the following is the nurse's best response?
a. "The cost is small compared to the benefits your child will receive, so you need to do this for your child." b. "Growth hormone can cost $30,000 per year or more; however, let's check what your insurance and special drug company programs will cover." c. "Don't worry about the cost as there will somehow be a way to pay for it." d. "Why don't you ask your church to help you look for a way to deal with the cost of treatment for your child's delayed growth and development?"
The Pure Food and Drug Act (PFDA) of 1906 was significant in that it gave the government the power to prohibit drug labels from claiming false therapeutic benefits
However, there were still several weaknesses in the legislature of this act. Which statements most accurately describe these weaknesses? 1. This law did not require drug manufacturers to prove that the drug was effective in its claims. 2. This law did not prevent drugs from being marketed for any disease. 3. This law required all drug labels to accurately describe their contents. 4. This law required adequate testing for safety prior to marketing. 5. This law did not encourage the development of drugs for rare or unusual disorders.